Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 4:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–7 of 7 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: TAK-906 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants

NCT04454918
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-906 Oral Capsule, [14C]-TAK-906 Intravenous Infusion, [14C]-TAK-906 Oral Solution
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 6, 2022 · Synced Sep 4, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

NCT03849690
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-906, Esomeprazole
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Sep 4, 2026, 4:09 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Bioavailability and Food Effect Study of Two Formulations of TAK-906

NCT04831502
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-906
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Sep 4, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis

NCT03544229
View directory record Official record
Conditions
Diabetic Gastroparesis, Idiopathic Gastroparesis
Interventions
TAK-906 Maleate, Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
67
States / cities
Dothan, Alabama • Tucson, Arizona • Chula Vista, California + 54 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Sep 4, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)

NCT03268941
View directory record Official record
Conditions
Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis
Interventions
TAK-906 Maleate, Metaclopramide, TAK-906 Maleate Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Peoria, Arizona • Tucson, Arizona • Little Rock, Arkansas + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 4, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

NCT04121078
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-906, Rifampin
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Sep 4, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-906 in Healthy Participants

NCT03161405
View directory record Official record
Conditions
Healthy Participants
Interventions
TAK-906 Maleate, Itraconazole
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Sep 4, 2026, 4:09 PM EDT